The Web Search API Built for LLMs
Search More. Pay Less. Built for AI Agents.
Web-scale search that's 100× cheaper, 10× faster, accurate & fully independent.
$0.05
Per 1K queries
50ms
As fast as
40B+
Web Index Pages
Files
Conversations
Agents
Web
Reports
Documentation
Files
Conversations
Agents
Web
Reports
Documentation
The Problem
Search costs more than intelligence.
Search has quietly become the most expensive line item in the AI stack.
Ceramic.ai aligns search costs to inference costs so your AI can search every query, not just ration it. Search APIs cost up to $14 per 1K queries, while workhorse LLMs cost as little as $0.15 — search has become the dominant cost in the AI stack.
Search API cost comparison for AI agents and LLM pipelines
Grok-4-1-fast + Competitor search
Model $0.15
Search $14.00
Total / 1K queries $14.15
Grok-4-1-fast + Ceramic
Model $0.15
Search $0.05
Total / 1K queries $0.20
* Model cost based on output pricing at ~300 tokens per response (0.3M output tokens ≈ 1K queries)
Made by the people who invented fully web-scale search
Ceramic.ai was founded by Dr. Anna Patterson, former Google VP of Engineering and Product and inventor of TeraGoogle, and Dr. Tom Costello, Stanford AI PhD and founder of Cuil. They saw the next problem: search designed for AI, not for humans.
40B+ pages indexed · Launched Q2 2026 · Backed by NEA, Earthshot Ventures, IBM, Samsung Next & Mento VC
Ceramic.ai Web API
Ceramic.ai: More searches. More sources. Better answers.
The same question, three ways. More searches means more angles, fresher data, and better-grounded answers.
Query:
“What are the latest developments with GLP-1 weight loss drugs?”
No Search
LLM with no web access
0 Searches
GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) have become popular weight loss treatments. Wegovy received FDA approval for chronic weight management in 2021.
Outdated — training data cutoff
Competitor Search API
$14.00 per 1,000 queries *
- • GLP-1 weight loss drugs 2025
- • ozempic wegovy latest news
- • new obesity drugs FDA
3 Searches
The GLP-1 drug market has expanded significantly in 2025. Novo Nordisk's CagriSema showed up to 25% weight loss in late-stage trials. Supply shortages have largely been resolved, and Medicare coverage expanded following new cardiovascular benefit data. Eli Lilly's tirzepatide continues gaining market share.
Ceramic.ai Search
$0.05 per 1,000 queries
- • GLP-1 weight loss drugs 2025
- • CagriSema Phase 3 trial results
- • FDA wegovy label expansion
- • tirzepatide vs semaglutide efficacy
- • GLP-1 cardiovascular outcomes data
- • Medicare GLP-1 coverage policy 2025
- • ozempic supply chain status
- • oral semaglutide weight loss trials
- • Amgen MariTide Phase 3
- • GLP-1 drug pipeline 2025
- • obesity drug pricing trends
- • global weight loss drug market size
12 Searches
The GLP-1 landscape has transformed in 2025.[1] Novo Nordisk's CagriSema demonstrated 25.3% average weight loss in Phase 3, combining semaglutide with cagrilide.[2] The FDA expanded Wegovy's label to include cardiovascular risk reduction based on the SELECT trial.[3] Eli Lilly's tirzepatide achieved 22.4% weight loss in head-to-head comparisons.[4] Medicare Part D now covers GLP-1s for obesity following CMS policy changes.[5] Amgen's MariTide entered Phase 3 with a once-monthly dosing advantage.[6] The global obesity drug market is projected to reach $150B by 2030.[7]
4x
more searches
70x
cheaper
Use Cases
Any industry, any application – built on AI, powered by search.
Enterprise-Ready
Enterprise-Ready
Enterprise-grade privacy and compliance for teams running AI at scale.
Private Data Indexing
Index and search your internal knowledge. Your data never leaves your environment.
Custom Rate Limits
Limits tailored to your requirements. Scale with confidence.
Dedicated Support
A dedicated team to help you integrate, scale, and succeed.


SOC2 Certified


Zero Data Retention
To include your public data, add Allow: TerraCotta to your robots.txt.







